QUB researchers identify the impact of bacterial co-infections and antimicrobial resistance in Covid-19
A team of researchers from Queen’s University Belfast have identified new problems linked to Covid-19 and warned of a sharp rise in antimicrobial resistance associated with treatments in the aftermath of the pandemic.
Microbiologists Professor José Bengoechea and Dr Connor Bamford have highlighted Covid patients are at risk of developing severe bacterial infections.
In a new paper the researchers suggest potentially fatal bacterial respiratory infections may arise subsequently or co-incidentally from hospital stays and therapies given to treat patients.
Co-existing bacterial infection alongside the virus may worsen the clinical outcome and the severity of Covi-19 in a patient, increasing the risk of death, they have suggested.
The paper highlights how SARS-CoV-2 and bacteria in the lungs may affect each other’s ability to cause damage, and with the immune response to the virus being different when bacteria are present, the clinical outcome and the severity of Covid-19 in a patient could worsen.
Tributes continue to pour in from across political divide for talented footballer Molly White - 'you will never be replaced'
Northern Ireland nurse uses can of spray paint to make life easier for patient
Which side of the bed do you sleep on? Here’s what it says about your personality
Ould Lammas Fair to return this year in Ballycastle after two years absence
Occupational therapist wins Catalyst Impact Award because ‘Seating Matters’
The paper also suggests the likeliness of the gut microbiota being disrupted in severe patients, which may affect disease outcomes.
Professor Bengoechea said: “The lack of therapies to treat severe Covid-19 patients led clinicians to use a number of treatments to modify the activity of their immune system.
“However, it is important to note that these interventions may also increase the risk of potentially fatal secondary bacterial respiratory infections.”
He added: “Therefore, careful consideration should be given whether any potential new therapy may affect the patients’ defenses against bacterial infections.”